E-resources
-
Stahl, Maximilian; Shallis, Rory M; Wei, Wei; Montesinos, Pau; Lengline, Etienne; Neukirchen, Judith; Bhatt, Vijaya R; Sekeres, Mikkael A; Fathi, Amir T; Konig, Heiko; Luger, Selina; Khan, Irum; Roboz, Gail J; Cluzeau, Thomas; Martínez-Cuadron, David; Raffoux, Emmanuel; Germing, Ulrich; Umakanthan, Jayadev Manikkam; Mukherjee, Sudipto; Brunner, Andrew M; Miller, Adam; McMahon, Christine M; Ritchie, Ellen K; Rodríguez-Veiga, Rebeca; Itzykson, Raphaël; Boluda, Blanca; Rabian, Florence; Tormo, Mar; Acuña-Cruz, Evelyn; Rabinovich, Emma; Yoo, Brendan; Cano, Isabel; Podoltsev, Nikolai A; Bewersdorf, Jan Philipp; Gore, Steven; Zeidan, Amer M
Leukemia, 12/2020, Volume: 34, Issue: 12Journal Article
Hyperleukocytosis in acute myeloid leukemia (AML) is associated with inferior outcomes. There is limited high quality evidence to support the benefits of leukapheresis. We retrospectively collected data from patients with newly-diagnosed AML who presented with a white cell count (WBC) >50 × 10 /L to 12 centers in the United States and Europe from 2006 to 2017 and received intensive chemotherapy. Logistic regression models estimated odds ratios for 30-day mortality and achievement of composite complete remission (CRc). Cox proportional hazard models estimated hazard ratios for overall survival (OS). Among 779 patients, clinical leukostasis was reported in 27%, and leukapheresis was used in 113 patients (15%). Thirty-day mortality was 16.7% (95% CI: 13.9-19.3%). Median OS was 12.6 months (95% CI: 11.5-14.9) among all patients, and 4.5 months (95% CI: 2.7-7.1) among those ≥65 years. Use of leukapheresis did not significantly impact 30-day mortality, achievement of CRc, or OS in multivariate analysis based on available data or in analysis based on multiple imputation. Among patients with investigator-adjudicated clinical leukostasis, there were statistically significant improvements in 30-day mortality and OS with leukapheresis in unadjusted analysis, but not in multivariate analysis. Given the significant resource use, cost, and potential complications of leukapheresis, randomized studies are needed to evaluate its value.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.